Systemic administration of human umbilical cord‑derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID‑19 with multiple comorbidities: A case report

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and has become a public health emergency, principally due to the severe inflammatory response and cytokine storm, as well as the deficiency of specific vaccines and antiviral drugs. Despite the fact that mesenchymal stem cells (MSCs) are acknowledged to possess unique immunomodulatory capabilities and have promising prospects in regenerative medicine, the efficacy of the use of MSCs on critically ill elderly patients with COVID-19 is largely obscure. In the present study, a 75-year-old male patient critically ill with COVID-19 was enrolled with multiple concomitant diseases, including hypertension (for >10 years), diabetes and coronary heart disease (for >1 year). Systemic infusions of 5x10 7 human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) were accomplished through intravenous injection every 3 days for 3 times following the consents of the patient and the relevant ethics committee. The clinical and functional outcomes, including general symptoms, vital signs, hemogram, chest radiography and the disease score, together with inflammatory factors and SARS-CoV-2 nucleic acid detection, were observed and dynamically recorded for 1 month. With the aid of hUC-MSC administration, the severe COVID-19-associated symptoms of the elderly patient, and in particular, pneumonia and the cytokine storm were continuously ameliorated. Moreover, the outcomes of multiple concomitant diseases were improved, whereas no deterioration and secondary infections, such as fever and allergic reaction were observed. The present study thus indicated that hUC-MSC administration can ameliorate the outcomes of patients with COVID-19. This type of treatment may prove to be an ideal alternative option for the treatment of patients with COVID-19, even for critically ill elderly patients with multisystemic complications.

Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

“…In the case of COVID-19 patients with pneumonia or ARDS, several clinical trials have also been registered in www.clinicaltrial.gov so far, but only a few of them have been completed and published their results [ 22 , 31 ]. For example and in the same direction, 7 COVID-19 patients who did not get beneficial results from common standard care were included in a pilot study performed by Leng et al and received 1 × MSCs/kg BW.…”

Umbilical cord tissue-derived mesenchymal stem cells should be considered as adjuvant therapy for COVID-19 treatment: An opinion from pooled clinical evidence

“…In 16 publications (included 6 case reports), 9 studies used fresh UC-MSCs prepared in the laboratory 5,24-26,28,32,33,36 , 4 studies used freshly thawed cryopreserved UC-MSCs that had not been refreshed by in vitro culture before use 27,30,34, 38 , and 1 study used UC-MSCs that had been shipped and maintained at 8-12 • C for less than 6 h before they were used 38 . Two studies did not provide information regarding whether their UC-MSCs were fresh or thawed 35,37 . With the limitation of patients and studies, it is difficult to demonstrate and compare the efficacy of fresh or cool-kept and freshly thawed UC-MSCs with respect to COVID-19 treatment.…”